# Superiority of MACI® Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the Knee

> **NCT00719576** · PHASE3 · COMPLETED · sponsor: **Vericel Corporation** · enrollment: 144 (actual)

## Conditions studied

- Articular Cartilage Defect

## Interventions

- **BIOLOGICAL:** autologous cultured chondrocytes on porcine collagen membrane
- **PROCEDURE:** Microfracture

## Key facts

- **NCT ID:** NCT00719576
- **Lead sponsor:** Vericel Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2021-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00719576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00719576, "Superiority of MACI® Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the Knee". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00719576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*